Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds

British Journal of Cancer

Volumn 81, Issue 5, 1999, Pages 800-807

  Van Hille, B ^a   Clerc, X ^a   Creighton, A M ^b   Hill, B T ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bisdioxopiperazine; DNA repair; Human; RAD52; Topoisomerase I; Yeast

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; PIPERAZINE DERIVATIVE;

ARTICLE; COMPARATIVE STUDY; DNA ADDUCT; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG SCREENING; EXPRESSION VECTOR; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; YEAST;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FUNGAL PROTEINS; HUMANS; PIPERAZINES; RAD52 DNA REPAIR AND RECOMBINATION PROTEIN; RAZOXANE; REPRODUCIBILITY OF RESULTS; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS;

EID: 0032699010     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690767     Document Type: Article

References (38)

1. Abe H, Wada M, Kohno K and Kuwano M (1994) Altered drug sensitivities to anticancer agents in radiation-sensitive DNA repair deficient yeast mutants. Anticancer Res 14: 1807-1810
2. Andoh T and Ishida R (1998) Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta 1400: 155-171
3. Ausubel FM, Brent R, Kingston RE, More DD, Seidman JG, Smith JA and Struhl K (1995) Current Protocols in Molecular Biology. Current Protocols: Boston
4. Barret J-M and Hill BT (1998) DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets. Anticancer Drugs 9: 105-123
5. 2 arrest and lethality. Cancer Res 57: 1970-1980
6. Bjornsti MA, Benedetti P, Viglianti GA and Wang JC (1989) Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity to the antitumor drug camptothecin. Cancer Res 49: 6318-6323
7. Chaney SG and Sancar A (1996) DNA repair, enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 88: 1346-1360
8. Chen AY and Liu LF (1994) DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34: 191-218
9. Corbett AH and Osheroff N (1993) When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplasic drugs. Chem Res Toxicol 6: 585-597
10. Creighton AM (1971) Piperazine derivatives. UK Patent 1234935.
11. Creighton AM (1974) 3,5-Dioxopiperazine derivatives. UK Patent 1374979.
12. DeVita VT Jr, Hellman S and Rosenberg SA (1993) Cancer, Principles and Practice of Oncology, 4th edn. JB Lippincott, Philadelphia
13. Eng WK, Faucette L, Johnson RK and Sternglanz R (1988) Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34: 755-760
14. Friedberg EC, Siede W and Cooper AJ (1991) Responses to DNA damage in yeast, In: The Molecular and Cellular Biology of the Yeast Saccharomyces, Broach JR, Pringle JR and Jones EW (eds). pp. 147-192, Cold Spring Harbor Laboratory Press: Cold Spring Harbor
15. Hasinoff BB, Kushchak TT, Yalowich JC and Creighton AM (1995) A qsar study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 50: 953-958
16. Hasinoff BB, Reinders FX and Clarck V (1991) The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1 yl)propane. Drug Metab Disposition 19: 74-80
17. Hays SL, Firmenich AA and Berg P (1995) Complex formation in yeast double strand breaks repair: participation of rad51, RAD52, rad55, and rad57 proteins. Proc Natl Acad Sci USA 92: 6925-6929
18. Ishida R, Hamatake M, Wasserman RA, Nitiss JL, Wang JC and Andoh T (1995) DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res 55: 2299-2303
19. Johnson SA, Harper P, Hortobagyi GN and Pouillart P (1996) Vinorethine: an overview. Cancer Treat Rev 22: 127-142
20. Kingsbury WD, Bochin JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK and Hertzberg RP (1991) Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98-107
21. Milne GT and Weaver DT (1993) Dominant negative alleles of RAD52 reveals a DNA repair/recombination complex including Rad51 and RAD52. Genes Dev 7: 1755-1765
22. Nitiss J and Wang JC (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA 85: 7501-7505
23. Osheroff N (1989) Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmac Ther 41: 223-241
24. Pinedo HM, Longo DL and Chabner BA (1997) Cancer Chemotheraphy and Biological Response Modifiers Annual 17. Elsevier: Amsterdam
25. Pommier Y, Tanizawa A and Kohn KW (1994) Mechanisms of topoisomerase I inhibition by anticancer drugs. Adv Pharmacol 29B: 73-92
26. Ramotar D and Masson JY (1996) Saccharomyces cerevisiae DNA repair processes: an update. Mol Cell Biochem 158: 65-75
27. Roca J, Ishida R, Bergee JM, Andoh T and Wang JC (1994) Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91: 1781-1785
28. Sehested M and Jensen PR (1996) Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 51: 879-886
29. Sehested M, Buhl P, Sorensen BS, Holm B, Friche E and Demant EJF (1993) Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5 dioxopiperazinyl-1 yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 46: 389-393
30. Shen DW, Akiyama SI, Schoenlein P, Pastan I and Gottesman MM (1995) Characterisation of high-level cisptatin-resistant cell lines established from cross-resistance and protein changes. Br J Cancer 71: 676-683
31. Subramanian D, Rosenstein BS and Muller MT (1998) Utraviolet-induced DNA damage stimulates topoisomerase I DNA complex formation in vivo: possible relationship with DNA repair. Cancer Res 58: 976-984
32. Thielmann HW, Popanda O, Gersbach H and Gilberg F (1993) Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts. Carcinogenesis 14: 2341-2351
33. Utsugi T, Shibata J, Sugimoto Y, Aoyagi K, Wierzba K, Kobunai T, Terada T, Oh Hara T, Tsuro T and Yumada Y (1996) Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Cancer Res 56: 2809-2814
34. van Hille B and Hill BT (1998) Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterisation of topoisomerase II-targeting antitumor agents. Cancer Chemother Pharmacol 42: 345-356
35. Van Rosmalen A, Cullinane C, Cutts SM and Phillips Don R (1995) Stability of adriamycin-induced DNA adducts and intrastrand crosslinks. Nucleic Acids Res 23: 42-50
36. Wall ME, Wani MC, Cooke CE, Palmer KH, McPhail AT and Slim GA (1966) Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888-3890
37. Wang JC (1985) DNA topoisomerases. Annu Rev Biochem 54: 665-697
38. Wood RD (1996) DNA repair in eukaryotes. Annu Rev Biochem 65: 135-167